[1] ALLISON K, PATEL D, ALABI O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020;12(11):e11686.
[2] LIU W, LIU S, LI P, et al. Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies. Int J Mol Sci. 2022;23(9):4883.
[3] GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2): e130-e143.
[4] LIM R. The surgical management of glaucoma: A review. Clin Exp Ophthalmol. 2022;50(2):213-231.
[5] BUCKINGHAM BP, INMAN DM, LAMBERT W, et al. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci. 2008;28(11):2735-2744.
[6] HOON M, OKAWA H, DELLA SANTINA L, et al. Functional architecture of the retina: development and disease. Prog Retin Eye Res. 2014;42:44-84.
[7] YUAN F, WANG M, JIN K, et al. Advances in Regeneration of Retinal Ganglion Cells and Optic Nerves. Int J Mol Sci. 2021;22(9):4616.
[8] HU Y, TAN HB, WANG XM, et al. Bone marrow mesenchymal stem cells protect against retinal ganglion cell loss in aged rats with glaucoma. Clin Interv Aging. 2013;8:1467-1470.
[9] REBOUSSIN É, BUFFAULT J, BRIGNOLE-BAUDOUIN F, et al. Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model. J Neuroinflammation. 2022;19(1):63.
[10] CHANG K, WU JG, MA TL, et al. Bioengineering strategy to promote CNS nerve growth and regeneration via chronic glutamate signaling. Acta Biomater. 2024; 190:165-177.
[11] IHADADENE K, FALLATAH AHA, ZHU Y, et al. Inhibition of cGMP-Signalling Rescues Retinal Ganglion Cells From Axotomy-Induced Degeneration. J Neurochem. 2025; 169(4):e70072.
[12] HOLAN V, PALACKA K, HERMANKOVA B. Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials. Cells. 2021;10(3):588.
[13] ASHOK A, TAI WL, LENNIKOV A, et al. Electrical stimulation alters DNA methylation and promotes neurite outgrowth. J Cell Biochem. 2023;124(10):1530-1545.
[14] ROCCO ML, SOLIGO M, MANNI L, et al. Nerve Growth Factor: Early Studies and Recent Clinical Trials. Curr Neuropharmacol. 2018;16(10):1455-1465.
[15] ABRAHAM AK, TELIAS M. The role of neurotrophic factors in retinal ganglion cell resiliency. Front Cell Neurosci. 2025;19:1536452.
[16] MINNONE G, DE BENEDETTI F, BRACCI-LAUDIERO L. NGF and Its Receptors in the Regulation of Inflammatory Response. Int J Mol Sci. 2017;18(5):1028.
[17] GARCIA TB, HOLLBORN M, BRINGMANN A. Expression and signaling of NGF in the healthy and injured retina. Cytokine Growth Factor Rev. 2017;34:43-57.
[18] NYSTUEN A, GONZALEZ-LOPEZ E, KAUPER KA, et al. Neuroprotective properties of ciliary neurotrophic factor in the retina for the treatment of macular telangiectasia type 2. Cytokine Growth Factor Rev. 2025;84:12-19.
[19] PASQUIN S, SHARMA M, GAUCHAT JF. Ciliary neurotrophic factor (CNTF): New facets of an old molecule for treating neurodegenerative and metabolic syndrome pathologies. Cytokine Growth Factor Rev. 2015;26(5):507-515.
[20] LIU X, HAO F, HAO P, et al. Regeneration and functional recovery of the completely transected optic nerve in adult rats by CNTF-chitosan. Signal Transduct Target Ther. 2023;8(1):81.
[21] MüLLER A, HAUK TG, FISCHER D. Astrocyte-derived CNTF switches mature RGCs to a regenerative state following inflammatory stimulation. Brain. 2007;130(Pt 12): 3308-3320.
[22] GHOLAP AD, ROJEKAR S, KAPARE HS, et al. Chitosan scaffolds: Expanding horizons in biomedical applications. Carbohydr Polym. 2024;323:121394.
[23] JAFERNIK K, ŁADNIAK A, BLICHARSKA E, et al. Chitosan-Based Nanoparticles as Effective Drug Delivery Systems-A review. Molecules. 2023;28(4):1963.
[24] ZAMBOULIS A, NANAKI S, MICHAILIDOU G, et al. Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments. Polymers (Basel). 2020;12(7):1519.
[25] JIMÉNEZ-GÓMEZ CP, CECILIA JA. Chitosan: A Natural Biopolymer with a Wide and Varied Range of Applications. Molecules. 2020;25(17):3981.
[26] LIU X, DUAN H, GAO L, et al. Effects of NGF-chitosan on alleviating secondary degeneration and repairing primary degeneration after expanded partial optic nerve transection. Sci China Life Sci. 2025;68(8):2393-2407.
[27] BOYD JG, GORDON T. Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury. Mol Neurobiol. 2003;27(3):277-324.
[28] LAZZARA F, AMATO R, PLATANIA CBM, et al. 1α,25-dihydroxyvitamin D(3) protects retinal ganglion cells in glaucomatous mice. J Neuroinflammation. 2021;18(1): 206.
[29] AU NPB, MA CHE. Neuroinflammation, Microglia and Implications for Retinal Ganglion Cell Survival and Axon Regeneration in Traumatic Optic Neuropathy. Front Immunol. 2022;13:860070.
[30] LIU Y, ZENG R, WANG Y, et al. Mesenchymal stem cells enhance microglia M2 polarization and attenuate neuroinflammation through TSG-6. Brain Res. 2019; 1724:146422.
[31] ADORNETTO A, RUSSO R, PARISI V. Neuroinflammation as a target for glaucoma therapy. Neural Regen Res. 2019;14(3):391-394.
[32] LUCAS-RUIZ F, FERNÁNDEZ-NOGALES M, VALIENTE-SORIANO FJ, et al. Restorative potential of ciliary body cells in a retinal ganglion cell degeneration model. Sci Rep. 2025;15(1):15503.
[33] RAMSDEN CM, POWNER MB, CARR AJ, et al. Neural retinal regeneration with pluripotent stem cells. Dev Ophthalmol. 2014;53:97-110.
[34] HADDAD Y, ADAM V, HEGER Z. Trk Receptors and Neurotrophin Cross-Interactions: New Perspectives Toward Manipulating Therapeutic Side-Effects. Front Mol Neurosci. 2017;10:130.
[35] BARCELONA PF, SARAGOVI HU. A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo. Mol Cell Biol. 2015;35(19):3396-3408.
[36] GHOLAP AD, KAPARE HS, PAGAR S, et al. Exploring modified chitosan-based gene delivery technologies for therapeutic advancements. Int J Biol Macromol. 2024; 260(Pt 2):129581.
[37] VAKA SR, SAMMETA SM, DAY LB, et al. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci. 2009; 98(10):3640-3646.
[38] GEORGELOU K, SARIDAKI EA, APOSTOLIDOU CP, et al. Targeted Delivery of Microneurotrophin BNN27 via Biomaterial Grafts Protects Retinal Ganglion Cells After Optic Nerve Injury. J Biomed Mater Res B Appl Biomater. 2026;114(1): e70013.
[39] PFISTER LA, ALTHER E, PAPALOÏZOS M, et al. Controlled nerve growth factor release from multi-ply alginate/chitosan-based nerve conduits. Eur J Pharm Biopharm. 2008;69(2):563-572.
[40] HU Y, GRODZKI LM, BARTSCH U. Survival and Axonal Regeneration of Retinal Ganglion Cells in a Mouse Optic Nerve Crush Model After a Cell-Based Intravitreal Co-Administration of Ciliary Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor at Different Post-Lesion Time Points. Cells. 2025;14(9):643.
[41] GOKOFFSKI KK, PENG M, ALAS B, et al. Neuro-protection and neuro-regeneration of the optic nerve: recent advances and future directions. Curr Opin Neurol. 2020;33(1):93-105.
[42] JU WK, PERKINS GA, KIM KY, et al. Glaucomatous optic neuropathy: Mitochondrial dynamics, dysfunction and protection in retinal ganglion cells. Prog Retin Eye Res. 2023;95:101136.
[43] HAIDER A, KHAN S, IQBAL DN, et al. Chitosan as a tool for tissue engineering and rehabilitation: Recent developments and future perspectives - A review. Int J Biol Macromol. 2024;278(Pt 1):134172.
[44] SONG W, DAI R, LI M, et al. Unidirectional and sustainable release of NGF and BDNF from a chitosan gel-mediated multilayer ordered composite membrane in promoting both spinal cord and sciatic nerve injury repair. Int J Biol Macromol. 2025;290:138927.
[45] ZEPPIERI M, VISALLI F, MUSA M, et al. Novel developments in retinal regeneration: Advances and future outlooks in stem cell therapy. World J Stem Cells. 2025; 17(12):111374.
[46] BHATTACHARYA S, DEKA J, AVALLONE T, et al. The neuroimmune interface in retinal regeneration. Prog Retin Eye Res. 2025;106:101361.
[47] HAO P, DUAN H, HAO F, et al. Neural repair by NT3-chitosan via enhancement of endogenous neurogenesis after adult focal aspiration brain injury. Biomaterials. 2017;140:88-102.
[48] CHAI M, SU G, GAO J, et al. Molecular Mechanism of the Protective Effects of M2 Microglia on Neurons: A Review Focused on Exosomes and Secretory Proteins. Neurochem Res. 2022;47(12):3556-3564.
[49] ZHOU G, CHEN Y, DAI F, et al. Chitosan-based nerve guidance conduit with microchannels and nanofibers promotes schwann cells migration and neurite growth. Colloids Surf B Biointerfaces. 2023;221:112929.
[50] PELUSI L, HURST J, DETTA N, et al. Effects of mesenchymal stromal cells and human recombinant Nerve Growth Factor delivered by bioengineered human corneal lenticule on an innovative model of diabetic retinopathy. Front Endocrinol (Lausanne). 2024;15:1462043.
[51] SUBRAMANI M, LAMBRECHT B, AHMAD I. Human microglia-derived proinflammatory cytokines facilitate human retinal ganglion cell development and regeneration. Stem Cell Reports. 2024;19(8):1092-1096.
[52] FAN W, HUANG W, CHEN J, et al. Retinal microglia: Functions and diseases. Immunology. 2022;166(3):268-286.
[53] SALKAR A, PALANIVEL V, BASAVARAJAPPA D, et al. Retinal glial cells in glaucoma and age-related retinal diseases: Inflammatory responses, disease transitions, and translational perspectives. Neural Regen Res. 2026;21(10):4822-4831.
[54] XIAO R, HUANG X, GAO S, et al. Microglia in retinal diseases: From pathogenesis towards therapeutic strategies. Biochem Pharmacol. 2024;230(Pt 1):116550.
|